Table 1.
Basic characteristics of study participants from GECCO*
| Study | Abbreviation | Number of cases |
Number of controls |
% Female |
Mean age (y) |
Mean BMI (kg/m2) |
Mean alcohol use (g/d) |
% Ever smokers |
% Regular users of aspirin/NSAIDs |
|---|---|---|---|---|---|---|---|---|---|
| Diet, Activity and Lifestyle Study | DALS | 1,100 | 1,165 | 44.9 | 64 | 27.1 | 10.0 | 54.0 | 37.8 |
| Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial | PLCO | 419 | 667 | 41.6 | 64 | 27.5 | 13.0 | 55.1 | 47.4 |
| Women’s Health Initiative | WHI | 1,429 | 1,502 | 100 | 66 | 27.9 | 5.3 | 50.4 | 35.6 |
| Darmkrebs: Chancen der Verhütung durch Screening | DACHS | 2,247 | 2,075 | 39.9 | 69 | 26.7 | 15.2 | 57.8 | 28.2 |
| Hawaii Colorectal Cancer Studies 2 & 3 (Colo2&3) | Colo2&3 | 75 | 104 | 44.8 | 65 | 26.1 | 12.4 | 54.7 | 38.1 |
| Health Professionals Follow-up Study | HPFS | 336 | 324 | 0 | 65 | 25.8 | 13.3 | 57.3 | 46.7 |
| Multiethnic Cohort Study | MEC | 304 | 316 | 46.4 | 63 | 26.4 | 17.9 | 64.8 | 40.5 |
| Nurses’ Health Study | NHS | 486 | 841 | 100 | 60 | 25.5 | 5.9 | 57.2 | 35.4 |
| Physicians’ Health Study | PHS | 375 | 386 | 0 | 59 | 25.0 | 8.7 | 58.4 | 48.0 |
| VITamins And Lifestyle | VITAL | 249 | 251 | 47.6 | 67 | 27.5 | 9.9 | 59.4 | 47.9 |
*
Abbreviations: BMI = body mass index; GECCO = the Genetics and Epidemiology of Colorectal Cancer Consortium; NSAID = non-steroidal anti-inflammatory drug.